Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Rhea-AI Summary
Arcutis (Nasdaq: ARQT) announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, held June 8–10, 2026.
A fireside chat is scheduled for Tuesday, June 9, 2026, at 2:00 p.m. ET, with a webcast and 180-day replay on the company website.
Positive
- None.
Negative
- None.
News Market Reaction – ARQT
In the May 27 session, ARQT gained 0.19%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 08 | Inducement equity grants | Neutral | +0.3% | Reported RSUs and stock options for 40 newly hired employees. |
| May 06 | Q1 2026 earnings | Neutral | -14.5% | Released Q1 financials, cash flow details, guidance, and pipeline updates. |
| Apr 27 | sNDA submission | Positive | +0.7% | Filed sNDA to expand ZORYVE cream use in infant atopic dermatitis. |
| Apr 22 | Guideline recommendation | Positive | +1.8% | ZORYVE cream received strong recommendation in pediatric AD guidelines. |
| Apr 15 | Earnings date notice | Neutral | -1.6% | Announced date and time for Q1 2026 results call and webcast. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive dermatology and regulatory updates have aligned with modest share gains, while the latest earnings release coincided with a sharper decline, suggesting sensitivity to financial updates versus steady reception of clinical and guideline news.
Over the past six weeks, ARQT has reported several developments. A May 6, 2026 Q1 update included strong ZORYVE revenue but led to a -14.52% move. Clinical and regulatory progress for ZORYVE, including an sNDA filing on Apr 27 and a strong guideline recommendation on Apr 22, saw modest positive reactions of 0.69% and 1.79%. Routine items like inducement grants and earnings date notices generated only small moves. Today’s conference appearance fits into this stream of ongoing investor communications.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WESTLAKE VILLAGE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the Goldman Sachs 47th Annual Global Healthcare Conference, taking place June 8-10, 2026, in Miami.
Details for the Company’s participation are as follows:
Fireside Chat: Tuesday, June 9, 2026, at 2:00 p.m. ET
The webcast for this conference may be accessed via the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform, coupled with our dermatology expertise, allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com
